Skip to main content

After high hopes for Merck’s COVID-19 pill, Wall Street now expects a ‘tepid’ authorization

It’s likely that Merck’s COVID-19 pill will be authorized in the U.S. this month but it's expected to be restricted to certain high-risk people.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.